News

When the immune system overreacts and starts attacking the body, the only option may be to shut the entire system down and risk developing infections or cancer. But now, scientists at UC San Francisco may have found a more precise way to dial it down. The technology uses engineered T cells that act

Nearly 50 UC San Francisco researchers have been named to Clarivate’s list of most influential scientists for 2024. 21 Cancer Center Members: Alan Ashworth, PhD Neal L. Benowitz, MD Atul J. Butte, MD, PhD Adil I. Daud, MD Felix Y. Feng, MD Lawrence Fong, MD Kathleen M. Giacomini, PhD Martin Kampmann

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells. For the same reason, designing new cancer drugs can be challenging due to the molecular

Alex Lee, PhD, a bioinformatician in the Sweet-Cordero lab, recently received an R50 training grant from the NCI. This salary-based award, which received a perfect score from reviewers, will allow Lee to explore additional research interests and collaborate with other labs in addition to his regular

When brain tumors recur, survival rates go down, and patients with the most lethal tumor type often die within a year. That’s because cancerous tissue is left behind after the initial surgery, and it continues to grow, sometimes even faster than the original tumor. Now a new study, led by UC San

New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new discipline in medicine, called cardio-oncology. Now teams from UC San Francisco and Stanford University